Novo Nordisk breaks up with small molecules; proteins feeling smug
Danish pharmaceutical maker Novo Nordisk has announced that it will cease research and development in small molecules for oral diabetes treatment, divesting existing projects such as NN9101 (a glucokinase activator project which is currently in phase 1 clinical testing). The company plans to focus its resources on therapeutic proteins, as it has done since 2002.
“Our core competences lie within therapeutic proteins, and it is within this area that we can make the greatest difference in terms of patient outcomes and company growth,” said Mads Krogsgaard Thomsen, chief science officer and executive vice president of Novo Nordisk. “Therefore, it is a logical move to focus all our research and development efforts on this area.”
I can’t begin to express my feelings about this in words. It’s just too emotional for me right now. Too raw. Too…
Okay, you got me. I have no idea what this means.
(via Forbes.com)
0 opinions for Novo Nordisk breaks up with small molecules; proteins feeling smug
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: